Payment overview · 2025
General Payments
$136,383.33
208 reported records · 23 companies
Healthcare provider profile · identity verified
Henry Bernard Townsend, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · PLANO, TX · NPI 1922114354
Verified facts
What the public records show
CMS Open Payments records show Henry Bernard Townsend, M.D. received $136,383.33 in general payments during 2025 across 208 reported records.
ABBVIE INC. accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rinvoq, Simponi Aria, Tremfya.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Enbrel by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Simponi Aria by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported STELARA as an associated drug or biological on 23706 records involving 7279 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Stelara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tremfya by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65,651.16 | 48.1% | 75 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36,520.40 | 26.8% | 48 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $32,893.31 | 24.1% | 33 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $251.90 | 0.2% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $226.95 | 0.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.60 | 0.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $132.54 | 0.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.57 | 0.1% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $58.00 | 0.0% | 3 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $55.11 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.52 | 0.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.66 | 0.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.37 | 0.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.19 | 0.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.39 | 0.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $25.03 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.30 | 0.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.23 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.95 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.93 | 0.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.23 | 0.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.66 | 0.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.33 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $108,906.00 | 48 |
| Travel and Lodging | $17,837.96 | 30 |
| Consulting Fee | $5,085.00 | 3 |
| Food and Beverage | $4,554.37 | 127 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $41,796.67 | 35 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36,435.38 | 42 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $32,893.31 | 33 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $25,654.72 | 17 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $23,763.57 | 35 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $251.90 | 6 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $226.95 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.93 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.68 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $84.71 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.71 | 5 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $58.00 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $55.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $55.28 | 3 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $55.11 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.52 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.52 | 2 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.87 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $12.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SIMPONI ARIA simponi aria |
2025 | Simponi Aria | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | STELARA open payments reported associated product |
CMS Open Payments — General Payments 23706 supporting records · 7279 recipient NPIs · example record 1174257377 |
Stelara · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 523 | 145 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 375 | 77 |
| Prednisone | Prednisone | 357 | 108 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 310 | 77 |
| Gabapentin | Gabapentin | 103 | 30 |
| Enbrel Sureclick | Etanercept | 79 | 13 |
| Tramadol Hcl | Tramadol Hcl | 69 | 19 |
| Celecoxib | Celecoxib | 66 | 17 |
| Allopurinol | Allopurinol | 62 | 22 |
| Leflunomide | Leflunomide | 62 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 48 | 11 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Humira(Cf) Pen | Adalimumab | 43 | suppressed |
| Meloxicam | Meloxicam | 41 | 13 |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 40 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Rinvoq | Upadacitinib | 32 | suppressed |
| Xeljanz | Tofacitinib Citrate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Enbrel | Etanercept | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Stelara | Ustekinumab | 21 | suppressed |
| Actemra | Tocilizumab | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Orencia | Abatacept/Maltose | 19 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Simponi Aria | Golimumab | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tremfya | Guselkumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136,383.33 · 208 records | ABBVIE INC. | ABRYSVO, AREXVY, Bimzelx, CAPLYTA, COMIRNATY, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, JATENZO, KEVZARA, KRYSTEXXA, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, RINVOQ, Rybelsus, SAPHNELO, SHINGRIX, SIMPONI ARIA, SKYRIZI, TAVNEOS, TREMFYA, TZIELD, Tymlos, UBRELVY, VRAYLAR, WatchPATONE, Wegovy, XYOSTED, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rinvoq play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error